IL10R2 Overexpression Promotes IL22/STAT3 Signaling in Colorectal Carcinogenesis

Cancer Immunology Research

Volumn 3, Issue 11, 2015, Pages 1227-1235

  Khare, Vineeta ^a   Paul, Gregor ^a   Movadat, Oliver ^a   Frick, Adrian ^a   Jambrich, Manuela ^a   Krnjic, Anita ^a   Marian, Brigitte ^b   Wrba, Friedrich ^a   Gasche, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR 2; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR 1; INTERLEUKIN 22 RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN; UNCLASSIFIED DRUG; IL10RB PROTEIN, HUMAN; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN RECEPTOR; INTERLEUKIN-22 RECEPTOR; MESSENGER RNA; MICROSATELLITE DNA; RNA; STAT3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; COLORECTAL CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE MUCOSA; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL PROLIFERATION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; MUCOSAL IMMUNITY; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, MUCOSAL; INTERLEUKIN-10 RECEPTOR BETA SUBUNIT; INTESTINAL MUCOSA; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; RECEPTORS, INTERLEUKIN; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84957557636     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0031     Document Type: Article

References (38)

1. Mantovani A, Marchesi F. IL-10 and macrophages orchestrate gut homeostasis. Immunity 2014;40:637-9.
2. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
3. Paul G, Khare V, Gasche C. Inflamed gut mucosa: Downstream of interleukin-10. Eur J Clin Invest 2012;42:95-109.
4. Kominsky DJ, Campbell EL, Ehrentraut SF, Wilson KE, Kelly CJ, Glover LE, et al. IFN-gamma-mediated induction of an apical IL-10 receptor on polarized intestinal epithelia. J Immunol 2014;192:1267-76.
5. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033-45.
6. Grundtner P, Gruber S, Murray SS, Vermeire S, Rutgeerts P, Decker T, et al. The IL-10R1 S138G loss-of-function allele and ulcerative colitis. Genes Immun 2009;10:84-92.
7. Gruber SG, Gloria LM, Grundtner P, Zdanov A, Gasche C. Differential signaling of cmvIL-10 through common variants of the IL-10 receptor 1. Eur J Immunol 2008;38:3365-75.
8. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996;98:1010-20.
9. Spencer SD, Di Marco F, Hooley J, Pitts-Meek S, Bauer M, Ryan AM, et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 1998;187:571-8.
10. Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S, Wang J, et al. Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 2001;22:665-71.
11. HachimineD,UchidaK, AsadaM,Nishio A, Kawamata S, SekimotoG, et al. Involvement of Smad3 phosphoisoform-mediated signaling in the development of colonic cancer in IL-10-deficient mice. Int J Oncol 2008;32: 1221-6.
12. Zigmond E, Bernshtein B, Friedlander G,Walker Catherine R, Yona S, Kim K-W, et al. Macrophage-restricted interleukin-10 receptor deficiency, but Not IL-10 deficiency, causes severe spontaneous colitis. Immunity 2014;40:720-33.
13. Josephson K, Logsdon NJ, Walter MR. Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity 2001; 15:35-46.
14. Kotenko SV, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka S. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J 1997;16:5894-903.
15. Finsterbusch M, Khare V, Campregher C, Evstatiev R, Gasche C. An intracytoplasmic IL-10 receptor variant permits rapid reduction in STAT3 activation. Genes Immun 2011;12:575-81.
16. Bromberg JF, WrzeszczynskaMH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
17. Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, et al. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta 2014;1845:136-54.
18. De Simone V, Franze E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, et al. Th17-type cytokines, IL-6 and TNF-alpha synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene 2014;34:3493-3503.
19. Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 2013;210:917-31.
20. Atreya R, Neurath MF. Signaling molecules: The pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Target 2008;9:369-74.
21. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005;129:969-84.
22. Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B, et al. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 2006;177:8266-72.
23. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST,Otte JM, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006;290:G827-38.
24. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002; 277:33676-82.
25. Herbeuval JP, Lelievre E, Lambert C, Dy M, Genin C. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophagederived IL-6. J Immunol 2004;172:4630-6.
26. Campregher C, Schmid G, Ferk F, Knasmuller S, Khare V, Kortum B, et al. MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells. PloS one 2012;7:e50541.
27. Khare V, Lyakhovich A, Dammann K, Lang M, Borgmann M, Tichy B, et al. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol 2013;85:234-44.
28. Khare V, Lang M, Dammann K, Campregher C, Lyakhovich A, Gasche C. Modulation of N-glycosylation by mesalamine facilitates membranous Ecadherin expression in colon epithelial cells. Biochem Pharmacol 2014; 87:312-20.
29. Ponchel F, Toomes C, Bransfield K, Leong FT, Douglas SH, Field SL, et al. Real-time PCR based on SYBR-Green I fluorescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 2003;3:18.
30. Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS, et al. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: A frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 1997; 57:1769-75.
31. Kleivi K, Teixeira MR, Eknaes M, Diep CB, Jakobsen KS, Hamelin R, et al. Genome signatures of colon carcinoma cell lines. Cancer Genet Cytogenet 2004;155:119-31.
32. Geremia A, Arancibia-Carcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011;208:1127-33.
33. Gasche C, Bakos S, Dejaco C, Tillinger W, Zakeri S, Reinisch W. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J Clin Immunol 2000;20:362-70.
34. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: An overview. Cancer Prev Res 2012;5:164-78.
35. Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, et al. IL-22(+)CD4 (+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.Immunity 2014;40:772-84.
36. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 2009;31:15-23.
37. Behnsen J, Jellbauer S,Wong CP, Edwards RA, George MD, Ouyang W, et al. The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. Immunity 2014;40:262-73.
38. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87 e3.